Investor Presentaiton

Research framework plus tumor intrinsic and extrinsic strategy will deliver productivity in Oncology Causal human biology Tumor Intrinsic Oncogenic Mechanisms repotrectinib in ROS1+ lung cancer, RAS signaling (SHP2 inhibitor) Lineage-specific targets AR LDD in prostate cancer, anti-ganglioside fucosyl-GM1 in SCLC Cancer cell vulnerabilities Context specific dependencies (e.g., DNA damage), synthetic lethal interactions Matching modality to mechanism Oncogenic Drivers Immune Checkpoints Lineage Specific Adaptive and Innate Immunity DNA Damage Stroma Synthetic Lethal 88 Path to clinical proof-of-concept Tumor Extrinsic Next-gen T cell CPIs Anti-CTLA4 next-gen, anti-TIGIT bi- specific, dual DGKα/ inhibitor Other immune cells Tregs Anti-CCR8 Myeloid Anti-ILT4 NK cells - Anti-NKG2A Neoantigens Aberrant Stromal Biology JNK inhibitor, TGFB inhibitor Ill Bristol Myers Squibb™ Not for Product Promotional Use 25

View entire presentation